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Abstract
The reservoir of human immunodeficiency virus type 1 (HIV-1), a long-lived pool of latently infected cells harboring
replication-competent viruses, is the major obstacle to curing acquired immune deficiency syndrome (AIDS).
Although the combination antiretroviral therapy (cART) can successfully suppress HIV-1 viremia and significantly
delay the progression of the disease, it cannot eliminate the viral reservoir and the patient must continue to take
anti-viral medicines for life. Currently, the appearance of the ‘Berlin patient’, the ‘Boston patients’, and the ‘Mississippi
baby’ have inspired many therapeutic strategies for HIV-1 aimed at curing efforts. However, the specific eradication of
viral latency and the recovery and optimization of the HIV-1-specific immune surveillance are major challenges to
achieving such a cure. Here, we summarize recent studies addressing the mechanisms underlying the viral latency and
define two categories of viral reservoir: ‘shallow’ and ‘deep’. We also present the current strategies and recent advances
in the development of a functional cure for HIV-1, focusing on full/partial replacement of the immune system, ‘shock
and kill’, and ‘permanent silencing’ approaches.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) is the
causative pathogen of acquired immune deficiency syn-
drome ( AIDS), which has long been a global health con-
cern. Combination antiretroviral therapy (cART), also
known as highly active antiretroviral therapy (HAART),
is the use of a combination of three or more antiretro-
viral drugs to suppress HIV-1 to an undetectable level in
the blood plasma. It is one of the major medical suc-
cesses of the 20th century. It effectively suppresses viral
replication, improves the immune function, and signifi-
cantly decreases the morbidity and mortality of AIDS.
However, cART has many limitations: (i) it cannot eradi-
cate the latent HIV-1 reservoir; (ii) the patient must
maintain a lifelong treatment regimen, otherwise the
viremia will rapidly rebound; (iii) it has toxic effects that
some patients cannot tolerate; and (iv) it involves
considerable expense. Therefore, the development of
novel treatment methods that are not subject to these
limitations is a massive requirement worldwide.
Ever since cases of HIV-1 infection were first reported
in 1981, it has become a dream to cure the HIV-1 infec-
tion. There could be two categories of cure for HIV-1: a
‘sterilizing’ cure and a ‘functional’ cure. In most virus-
induced diseases, the term ‘cure’ refers to a ‘sterilizing’
cure, which indicates that no trace of virus remains in
the body. In 2009, the case of the ‘Berlin patient’ pro-
vided evidence that complete elimination of HIV-1 is
possible [1]. After receiving whole-body irradiation and
successful transplantation of bone marrow from a CCR5
delta32 (Δ32) homozygous donor, the ‘Berlin patient’
reached what was thought to be a ‘sterilizing’ cure, given
that no residual viruses were found several years after
discontinuation of cART [2]. This case greatly encour-
aged enthusiasm for the development of a ‘sterilizing’
cure, until the case of ‘Boston patients’ appeared. Two
patients suffering from both AIDS and lymphoma re-
ceived a wild-type-CCR5(+) allogeneic hematopoietic
stem cell transplantation (HSCT) in Boston. Although
the levels of plasma viral RNA and the proviral DNA in
peripheral blood mononuclear cells (PBMCs) remained
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undetectable after transplantation, viruses appeared
again in their blood after cART was interrupted for 12
or 32 weeks, respectively [3]. The case of the ‘Mississippi
baby’ was also a disappointment. This baby, whose
mother had an untreated HIV-1 infection, received
cART at 30 hours of age. The baby girl ceased cART
treatment at 18 months of age. Surprisingly, the proviral
DNA in PBMCs, the plasma viral RNA, and HIV-1 anti-
bodies remained undetectable in her body when she was
retested at 30 months [4]. In 2013, the girl’s doctors
announced that she may have been cured and it
seemed that the early treatment of HIV-1-infected ba-
bies could be a feasible strategy for curing them of
HIV-1 infection. Unfortunately, plasma viral RNA and
HIV-1 antibodies were detected in her blood when
she was 4 years old [5].
As the ‘sterilizing’ cure for HIV-1 is difficult to achieve,
a ‘functional’ cure for HIV-1 has become a global re-
search priority. A ‘functional’ cure for HIV-1 is defined
as a long-term host-mediated control of viral replication
and remission of the symptoms of HIV-1 infection in
the absence of antiretroviral therapy, even if replication-
competent viruses remain in the body [6]. A rare group
of individuals, termed ‘elite controllers’, spontaneously
maintain plasma viremia to levels below the limits of
clinical detection without cART treatment [7]. The
mechanisms by which elite controllers maintain their
viral loads as undetectable could involve several genetic
traits. Over-representation of certain MHC class 1 alleles
in elite controllers, such as class 1 HLA-B*57 and HLA-
B*27 alleles, has a strong correlation with HIV-1 control
capability [8, 9]. Potent HIV-1-specific CD8+ T cell re-
sponse, such as the production of more cytolytic pro-
teins and pro-inflammatory cytokines, can be found in
elite controllers [10, 11]. The enrichment of specific nat-
ural killer (NK) cell immunoglobulin-like receptors
(KIRs), such as KIR3DS1 and KIR3DL1, could also be a
mechanism of elite control [12]. Furthermore, neutraliz-
ing antibodies via antibody-dependent cell-mediated
cytotoxicity (ADCC) could also contribute to viral con-
trol, even though there have been conflicting results
regarding the correlation between increased ADCC ac-
tivity and elite controllers [13, 14]. Higher-degree DNA
methylation in HIV-1 promoter was found to account
for the delayed disease progression in elite controller
[15]. High-level expression of specific host restriction
factors (for example, Schlafen 11) have also been found
in elite controllers [7]. Collectively, the elite controllers
serve as a natural model for the ‘functional’ cure of
HIV-1 and the mechanisms underlying the phenomenon
could provide a road map for the control of HIV-1. Al-
though efforts to pursue both ‘functional’ and ‘sterilizing’
cures are in progress, it seems that a ‘functional’ cure for
HIV-1 is more feasible than a ‘sterilizing’ cure.
HIV-1 latency is the major obstacle to achieving
a cure
HIV-1 latency is a silent state in which the infected cells
harbor intact HIV-1 genomes without generating viral
particles. It can be divided into two forms: (i) pre-
integration latency, which exists in a form with incom-
plete reverse transcripts or a form with un-integrated
viral DNAs and has a short half-life lasting from one day
to several weeks [16]; and (ii) post-integration latency,
which is the major form of the viral reservoir and occurs
after the infected activated CD4+ T cells reverse back to
a resting state [17]. Because the resting CD4+ T cells that
harbor HIV-1 proviruses are mostly long-lived central
memory cells (TCM) and the integrated viral genome is
quite stable, it has been estimated that the HIV-1 reser-
voir has a half-life of 44 months and needs almost
73.4 years to be completely purged [18]. Recent work
has indicated that stem cell-like memory CD4+ T cells
(TSCM) are also part of the HIV-1 reservoir [19]. In
addition to resting CD4+ T cells, other cellular reservoirs
that might exist include monocytes, macrophages, den-
dritic cells, hematopoietic progenitor cells (HPCs), and
microglial cells [20, 21].
The mechanisms underlying the latency of HIV-1
have been studied extensively over the past few de-
cades [22, 23]. Recent studies have expanded the
knowledge base regarding many factors that might
affect the reservoir, including epigenetic modifications,
integration sites, and posttranscriptional regulations.
One line of evidence indicated that epigenetic modifi-
cations are accountable for the molecular mechanism
of HIV-1 latency [24]. Both histone deacetylase (such
as HDAC-1 and HDAC-2) and histone methyltrans-
ferases (such as G9a, Suv39H1, HP1 gamma, GLP,
and EZH2) facilitate the silencing of HIV-1 proviruses
[25–29]. Although DNA methylation can downregu-
late gene expression and therefore plays a role in
HIV-1 latency, there is also some disagreement re-
garding the correlation between the amount of CpG
methylation in HIV-1 long terminal repeat (LTR) and
HIV-1 latency [30, 31]. Earlier this year, a report
showed a proportion of HIV-1 viruses to be silenced
immediately upon invading the target cells in an in
vitro model. Some actively transcribed proviruses also
underwent slow inactivation [32]. The sudden silen-
cing and time-dependent LTR inactivation were found
to be positively correlated with polycomb repressive
complex 2 (PRC2)-mediated H3K27 trimethylation,
which is a repressive histone modification [32]. In
addition, the orientation of HIV-1 promoter inte-
grated into host genes has been reported to affect
HIV-1 expression, termed ‘transcriptional interference’
(TI) [33, 34]. TI caused by elongation complex read-
ing through HIV-1 promoter facilitates HIV-1 latency
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when viral DNA integrates into the introns of active
genes with the same promoter orientation as host
genes [34]. However, a conflicting result has shown
that TI caused by read-through only occurs when the
HIV-1 promoter was in an orientation opposite to
that of the host genes. When both promoters were in
the same orientation, HIV-1 gene expression could be
promoted [33]. Besides, low-level expression of a
HIV-1-encoded microRNA targeting the TATA-box
region of viral promoter also plays a role in HIV-1 latency
[35]. Posttranscriptional regulation is another molecular
mechanism of HIV-1 latency. Host-derived noncoding
RNAs (ncRNAs) regulate HIV-1 latency by affecting viral
mRNAs [36, 37] or the expression of the host genes that
are hijacked as HIV-1 co-factors [38].
It has been shown that many latently infected T cells
undergo clonal expansion in individuals treated with
cART [39, 40]. Some integration hotspots have been
found in many of the genes in clonally expanded T cells,
such as megakaryoblastic leukemia 2 (MKL2) and basic
leucine zipper transcription factor 2 (BACH2). As both
MKL2 and BACH2 are the genes closely related to cell
proliferation, the activation of those genes by viral inte-
gration or transcription could account for the persist-
ence of the infected cells [39–41]. In addition, the
maintenance of the CD4+ TCM viral reservoir is driven
by T cell survival signal and low-level antigen-driven
proliferation [42]. In contrast, the transitional memory
CD4+ T cells (TTM), which are the major reservoirs in
aviremic individuals, are maintained by interleukin-7
(IL-7)-driven homeostatic proliferation [42]. These two
cellular mechanisms can explain why clonally-expended
latently infected cells are frequently detected in individ-
uals treated with cART [39–41].
The frequency of latently infected resting memory
CD4+ T cells was once thought to be 1/106 [43]. How-
ever, it has recently been found that, in addition to these
inducible replication-competent proviruses, large quan-
tities of non-inducible proviruses have intact genomes
and normal LTRs from patients on cART [44]. A statis-
tical model showed the size of the latent reservoir to be
60 times larger than previously estimated. Among the
replication-competent proviruses, although only 1 % of
replication-competent viruses can be recovered from the
PBMCs by latency-reversing agents (LRAs), 11.7 % of
the non-inducible proviruses have intact genomes and
normal LTRs [44]. Even experiencing several rounds of
stimulation, the proviruses in these cells were still si-
lenced [44]. Conversely, the insufficiency of HIV-1-
encoded proteins may be involved in the formation of
different reservoirs. HIV-1 Tat, which is a transactivator
of transcription, undergoes various modifications during
its regulatory circuit [45–48]. Certain modifications may
promote its decay, which leaves the proviruses without
enough Tat for transcription. Based on the stochastic
gene expression model of HIV-1 Tat fluctuation, the Tat
feedback circuit is sufficient to control HIV-1 latency,
which is independent of the cellular state [49]. The pro-
viruses may be silenced in the cells that do not have
enough Tat, even if that cell has reached its maximum
activation. Therefore, if enough Tat protein accumulates,
the silenced viral reservoir could be activated by LRAs.
These new findings suggest that two levels of viral res-
ervoir may exist: the ‘shallow’ viral reservoir and the
‘deep’ viral reservoir. The ‘shallow’ viral reservoir con-
sists of the infected cells containing inducible proviruses,
most of which could be reactivated by LRAs. In contrast,
the infected cells harboring non-inducible proviruses
constitute the ‘deep’ viral reservoir, which cannot be
activated by current LRAs including the stimulating
agents for lymphocyte proliferation. However, the for-
mation of ‘deep’ viral reservoirs has not been fully
understood. It could be due to the special HIV-1 inte-
gration sites, the special epigenetic regulations includ-
ing DNA methylation or histone modifications, the
spatial organization of the genomes, the mediation of
the interactions of distal elements, or special cell sta-
tus, etc. [31, 32, 39–41, 44, 49]. More effort is needed
to clarify these mechanisms and further, more in vivo
evidence is required for the classification of these two
reservoirs.
Full or partial replacement of the immune system
through genetic modification: strategy 1 for the
functional cure of HIV-1
While the case of the ‘Berlin patient’ resulted in a suc-
cessful cure of HIV-1, the low frequency of matching
both CCR5Δ32 and HLA genotypes for allogeneic bone
marrow transplantation and the scarcity of patients suf-
fering from both HIV-1 infection and lymphoma/
leukemia must be considered. Thus, the replacement of
all or part of the immune system through genetic engin-
eering to produce CD4+ T cells resistant to HIV-1
infection is a more feasible strategy. Since CCR5 was
identified as the primary HIV-1 co-receptor and the
CCR5Δ32 CD4+ T cells were found to be resistant to
HIV-1 infection, the reduction or elimination of CCR5
expression have been pursued [50, 51]. Several genetic
approaches have been utilized to knock down CCR5 in
primary immune cells, including the use of ribozymes
[52], single-chain intracellular antibodies [53], trans-
dominant co-receptor mutants [54], or RNA interference
(RNAi) [55]. However, these strategies do not silence
CCR5 expression permanently. To reach this goal,
some gene editing technologies, including zinc finger
nucleases (ZFNs) and transcription activator-like ef-
fector nucleases (TALENs), have been used to knock
out the CCR5 gene [56, 57]. Several clinical trials using
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autologous infusions of CCR5-modified CD4+ T cells are
currently under way. They are listed at ClinicalTrials.gov
under ID numbers NCT00842634, NCT01252641, and
NCT01044654 [58]. However, some T lymphocyte-tropic
virus strains (X4 and R5X4) utilize CXCR4 as another
co-receptor and these viral strains are found in ap-
proximately 50 % of late-stage HIV-1-infected individ-
uals, supporting the therapeutic requirement targeting
CXCR4 [59, 60]. After inhibition or disruption of
CXCR4 in primary lymphocytes using siRNA [61] or
ZFNs [58], the CD4+ T lymphocytes became capable
of resisting CXCR4-tropic HIV-1 infection. To fully
protect cells from HIV-1 infection, both CXCR4 and
CCR5 genes must be disrupted in CD4+ T lymphocytes.
These double co-receptor negative cells were resistant to
both CCR5- and CXCR4-tropic HIV-1 infection in a hu-
manized mouse model [62], suggesting that this strategy is
a reasonable approach in HIV-1 functional cure. Recently,
CRISPR/Cas9 system as a novel method of gene editing
was used to disrupt CCR5 in T cell lines, primary CD4+ T
cells, or induced pluripotent stem cells (iPSCs) to make
them or their progeny cells resistant to HIV-1 infection
[63–65]. Moreover, the CRISPR/Cas9 system could also
be used as a long-lived intracellular defender to protect
cells from HIV-1 infection. Once the HIV-1 entered the
cells, the HIV-1-specific CRISPR/Cas9 could quickly in-
duce lethal mutations in the incoming viral DNAs or even
completely excise them [66, 67].
Shock and kill: strategy 2 for the functional cure
of HIV-1
As latently infected resting CD4+ T cells do not expose
viral antigen, the immune system cannot recognize and
destroy them. For this reason, the ‘shock and kill’ (also
known as ‘kick and kill’) strategy has been extensively
discussed. After reactivating latent viruses from the res-
ervoir, the immune surveillance system will recognize
and eradicate these HIV-1-expressing cells in various
ways, including cytotoxic T lymphocyte (CTL) response
or ADCC.
Shock
Several methods of reactivating latent HIV-1 have been
developed. Anti-CD3 monoclonal antibody, interleukin-
2 (IL-2), and tumor necrosis factor-α (TNF-α) were used
to activate HIV-1 replication from the latently infected
cells. However, given that the massive activation of
CD4+ T cells by these general lymphocyte activators
involves a high risk of systemic induction of proin-
flammatory cytokines, these strategies are currently
not used clinically. It has also been demonstrated that
IL-7 can activate HIV-1 latency [68]. However, clinical
trials of IL-7 administration in HIV-1-infected indi-
viduals treated with cART have indicated that IL-7
can mediate survival and expansion of latently in-
fected memory CD4+ T lymphocytes and promote
HIV-1 persistence [69].
Apparently, more specific LRAs are needed to specific-
ally activate HIV-1 latency. One feasible strategy is to
trigger the activity of NF-κB, a major host transcription
factor, in cells latently infected with HIV-1 for viral re-
activation. Some protein kinase C (PKC)-NF-κB pathway
activators, such as prostratin and bryostatin-1, can react-
ive viruses in vitro [70, 71]. As prostratin induces potent
upregulation of the transcription of several cytokines
[71], its cytokine-related toxicity should be carefully
evaluated in a clinical trial. Bryostatin-1, which has
already been evaluated in several clinical trials for
cancer, is currently undergoing clinical trial for HIV-1
latency (NCT02269605). Conversely, some histone dea-
cetylase inhibitors (HDACis), which can keep more his-
tones in a state of acetylation and loosen the condensed
chromatin structure, have been developed as LRAs.
Valproic acid (VPA), which has been approved to treat
neuropsychiatric conditions, could induce viral reactiva-
tion in resting CD4+ T cells from HIV-1-infected pa-
tients on cART [72]. A proof-of-concept study in four
volunteers showed that the combination therapy with
VPA and intensified cART led to a decrease in the num-
ber of latently infected cells in three of four patients
[73]. However, subsequent studies did not support these
data [74–76]. Vorinostat, also called suberoylanilide
hydroxamic acid (SAHA), significantly increases HIV-1
transcription in an ex vivo HIV-1 latency model [77]. It
has already been in phase I and II clinical trials. A
single-dose trial of vorinostat demonstrated that the ad-
ministration of the drug could reactivate HIV-1 latency
in vivo [78]. Other potent HDACis, such as romidepsin
(FK288) and panobinostat (LBH589), have entered clin-
ical trials [79, 80]. After romidepsin infusions, plasma
HIV-1 RNA was found to significantly increase at mul-
tiple post-infusion time points in five out of six HIV-1-
infected patients [80]. In a phase I/II clinical trial, pano-
binostat reactivated HIV-1 latency in vivo effectively but
did not reduce the number of latently infected cells, in-
dicating that this agent may need to be combined with
other LRAs to affect the HIV-1 reservoir [79]. Although
the reactivation potency of givinostat (ITF2357) and
belinostat (PXD101) have been demonstrated in cell
lines latently infected with HIV-1, their effects on HIV-1
latency need to be evaluated in vivo.
In addition, as histone methylation plays a major role in
chromatin-mediated repression of the HIV-1 promoter,
H3K9 histone methyltransferase inhibitors (HMTis), in-
cluding BIX01294, chaetocin, and 3-deazaneplanocin A
(DZNep), have been used to induce HIV-1 reactivation in
latently infected resting CD4+ T cells or Jurkat T cells
[27, 28, 81]. It is expected that the clinical trials of
Liu et al. BMC Medicine  (2015) 13:284 Page 4 of 12
HMTis for HIV-1 latency could be attempted in the
future. Interestingly, disulfiram, which has been used
to treat alcoholism for decades, was identified as an
HIV-1 LRA in an in vitro latency model [82]. In a
pilot study, disulfiram was found to be safe and led
to a transient increase in plasma HIV-1 RNA in a
subset of individuals [83]. The possible mechanism of
disulfiram on HIV-1 transcription is to reduce phos-
phatase and tensin homolog (PTEN) expression level,
which results in activation of the Akt signaling path-
way [84]. However, the administration of disulfiram alone
or in combination with a modified vaccinia Ankara-based
HIV-1 vaccine (MVA-B) is unable to reduce the size of
the latent reservoir [83, 85, 86]. Furthermore, it has been
demonstrated that bromodomain-containing protein 4
(BRD4) can interact with the P-TEFb complex. BRD4 is a
member of the bromodomain and extra terminal domain
(BET) family and a well-conserved transcriptional
regulator that recognizes and binds acetyl-lysine resi-
dues [87, 88]. By affecting BRD4 and P-TEFb inter-
action, BET bromodomain inhibitors, such as JQ-1
and I-Bet, potently reactivate HIV-1 latency [89, 90].
Recently, two groups showed that PKC agonists in
combination with BET bromodomain inhibitors or his-
tone deacetylase inhibitors robustly induced the rever-
sal of HIV-1 latency in vitro and ex vivo as effectively
as positive controls stimulated with PMA plus iono-
mycin or anti-CD3 plus anti-CD28 antibodies [91, 92].
The potent effect of LRA combinations indicates that
co-administration of different types of LRAs could be a
suitable means of reducing the size of viral reservoirs.
Kill
After latent viruses are reactivated by the LRAs, the
immune system could eradicate the virus-producing
cells. However, recent data indicated that CD8+ T cells
in HIV-1-infected individuals on cART cannot eliminate
latently infected cells even after successful reactivation
[93]. Therefore, the recovery of potent antiviral function
of the immune system is required for the ‘kill’ strategy.
A role for IFN-α-mediated clearance of HIV-1-infected
cells is supported by several studies in which the expres-
sion of perforin and granzyme in NK and CD8+ T cells
from patients with HIV-1 infection or melanoma was in-
creased by IFN-α immunotherapy [94, 95]. The adminis-
tration of pegylated IFN-α-2A to patients on cART was
found to be associated with decreased HIV-1 integration
and suppression of viral replication [96]. Importantly,
checkpoint blockage, which is currently used for cancer
immunotherapy, has been examined for HIV-1 treat-
ment. Programmed cell death protein 1 (PD-1), a T cell
surface receptor, is highly expressed on latently infected
CD4+ or CD8+ T cells in patients treated with cART.
High expression of PD-1 on HIV-1-specific CD4+ T cells
prevents the activation of T cell receptors (TCRs) and
leads to the inhibition of proliferation and secretion of
diverse cytokines, resulting in the failure of immune
surveillance that recognizes and kills the reactivated
HIV-1-infected CD4+ T cells [97–99]. Conversely, PD-1
blockage leads to the improvement of HIV-1-specific
CD8+ T cell proliferation and cytokine secretion [100, 101].
In the SIV-macaque model, anti-PD-1 antibodies re-
stored the function of SIV-specific CD4+ and CD8+ T
cells [102]. Therefore, anti-PD-1 antibodies could be
employed to enhance the CTL response of HIV-1-
specific CD8+ T cells.
Autologous adoptive transfer of HIV-1-specific CD8+
T cells is another way to directly enhance the CTL re-
sponse of patients on cART. This strategy has been
widely used in cancer immunotherapy [103–105]. Given
that CD8+ TCM cells possess the ability of self-renewal
and maintain robust responses over time, HIV-1-specific
CD8+ T cells from patients on cART can be expanded ex
vivo and persist in vivo for more than 84 days, suggest-
ing that more methods targeting CD8+ TCM cells in pa-
tients treated with cART could provide an expanded and
long-term immune response [106]. Although CTL re-
sponse plays a significant role in the clearance of
reservoir, HIV-1 can quickly mutate to evade the CTL
reorganization. Therefore, the predominance of CTL-
resistant viruses in the reservoir is a major barrier to
viral eradication. A systematic investigation of CTL es-
cape variants in reservoirs has recently been performed.
Results showed that some CTLs that recognize unmu-
tated epitopes can exist in every tested patient. These
broad-spectrum CTLs have potent antiviral activity and
can eliminate target cells both in vitro and in the hu-
manized mice generated with the bone marrow cells
from HIV-1-infected patients [107]. Therefore, strategies
utilizing this broad-spectrum viral-specific CTL response
could be further developed for the eradication of the
HIV-1 reservoir.
Some genetic modification strategies have been used
to enhance the specific response of CD8+ T cells to HIV-
1-infected cells. To achieve powerful and sustained CTL
responses by enhancing TCR binding affinity, artificial
TCR (aTCR) was generated by special phage display
technology [108]. Two groups have reported that CD8+
T cells transduced with HIV-1 Gag-specific SL9 aTCR
could lyse A2-SL9-expressing cells and effectively con-
trolled wild-type and mutant strains of HIV-1 in vitro
and in vivo [109, 110]. However, given that the off-target
toxicity of MAGE-A3-specific aTCR for myeloma and
melanoma in a clinical trial caused the death of some
patients [111], a clinical trial of HIV-1-infected patients,
NCT00991224, was suspended before any participant
was infused with A2-SL9-specific aTCR-transduced
CD8+ T cells [112]. Therefore, the safety and specificity of
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high affinity TCR-modified CD8+ T cells need to be care-
fully re-evaluated.
Recently, modifying CD8+ T cells with chimeric anti-
gen receptors (CARs) has become a hot topic in cancer
research. CARs are generated by combining an extracel-
lular antigen-binding domain with intracellular T cell
activation domains. The extracellular antigen-binding
domain could be the antigen-binding domain of the
antibody or natural molecular marker such as CD4,
which can interact with HIV-1 gp120. The most com-
mon intracellular domain is the CD3 zeta chain, which
is the signal transduction machinery for T cell receptors
[113]. Modifying CD8+ T cells with these CARs allows T
cells to retarget the immune system in a high-affinity,
TCR-independent, and MHC-unrestricted manner. The
clinical usage of CARs for cancer adoptive therapy has
been shown to be safe and highly effective, mediating re-
mission in approximately 80 % of acute lymphocytic
leukemia patients [114]. CAR-T cells can survive in the
human body for more than 11 years after infusion [115].
CD8+ T cells modified with HIV-1-targeting CARs
lysed HIV-1 gp120-expressing cells specifically in vitro
[116, 117]. However, the antiviral efficacy of first-
generation CAR-T in vivo was modest [118]. More re-
cently, a new generation of CARs has been developed
by including different parts of the signaling molecules,
such as 4-1BB and/or CD28, to promote cell-mediated
cytotoxicity, proliferation, and survival of the modified
CAR-T cells [119–121]. Additionally, to prevent the CD4-
CARs from functioning as HIV-1 entry receptors, some
novel CD4-CARs have been designed by co-expressing
with HIV-1 fusion inhibitor (for example, maC46, an ex-
tended form of enfuvirtide) or linking CD4 to a single
chain variable fragment of the 17b human monoclonal
antibody, termed ‘17b scFv’ [122, 123]. Thus, the new gen-
erations of HIV-1-specific CAR-T cells should be used to
enhance HIV-1-specific CTL response and their clinical
usage could eventually be seen.
More recently, several studies have demonstrated that
some HIV-1-specific broadly neutralizing monoclonal
antibodies (bNAbs) (for example PGT121, VRC01, and
VRC03) can block cell-cell transmission of HIV-1 and
suppress viral replication in primary CD4+ T cells from
patients on cART in vitro and also control viremia in in-
fected humanized mice or rhesus macaques effectively
[124–128]. This year, 3BNC117, a potent CD4-binding
site antibody entered clinical trial [129]. As 3BNC117 is
well tolerated and effective in controlling HIV-1 viremia,
bNAb therapy can be explored as a new strategy for
HIV-1 functional cure. Given that HIV-1 can quickly
mutate to escape from a single antibody, the combina-
tions of bNAbs have been tried in a HIV-1-infected
humanized mice model [124, 126]. These bNAb combi-
nations have shown long-term half-life in blood plasma
for an average of 60 days and resulted in a significant re-
duction in both viremia and cell-associated HIV-1 DNA.
Moreover, bNAbs plus a combination of LRAs also
showed a significant decrease in viral reservoir in hu-
manized mice [130]. Thus, the combinations of LRAs
and bNAbs could be developed as a therapeutic modality
for eradicating viral reservoir in clinic.
Render HIV-1 permanently silent: strategy 3 for
the functional cure of HIV-1
Until now, all of the cure strategies have been aimed at
reducing or eradicating the viral reservoir. However, re-
placing all or part of the immune system through gen-
etic modifications can only render uninfected cells
immune to HIV-1. The infected cells remain alive and
may proliferate. The ‘shock and kill’ strategy is based on
the prerequisite that the infected cells and the proviruses
should be reactivated. As the current ‘shock’ agents can-
not wake up HIV-1 proviruses in all the latently infected
cells, it is unlikely that the reservoir of HIV-1 will be
completely eradicated using these recent approaches.
Due to the non-inducible property of the ‘deep’ viral
reservoir, the ‘permanent silencing’ approach could be
considered as a suitable cure strategy. Unlike ‘shock and
kill’ strategies, this approach focuses on silencing or
locking the HIV-1 proviruses in cells. DNA hypermethy-
lation of viral promoter and enhancer has been shown
to be important to HIV-1 silencing [31]. The transcrip-
tional gene silencing (TGS) siRNAs or short hairpin
RNA (shRNA)-targeting NF-kB binding motifs in the
HIV-1 LTR successfully suppressed the production of
HIV-1 for up to one year [131, 132]. This suppression
was found to be associated with CpG methylation within
the 5′LTR and also achieved in NOJ mice reconstituted
with human PBMCs [131–133]. Another group used
mobilization-competent lentiviral vector to deliver small
noncoding RNA targeting HIV-1 LTR. They successfully
silenced HIV-1 for over one month without resistance
mutation in TZM-bl cells. This TGS of HIV-1 was ac-
complished through increasing silent epigenetic modifi-
cations, such as histone and DNA methylation [134].
However, increasing viral burden results in the loss of
the antiviral effect in primary CD4+ T cells [135]. Be-
sides, their TGS-based antisense RNAs activated tumor
suppressor p53. The delivery, efficiency, and safety of
RNA-mediated TGS must be considered in future
studies.
Alternatively, many therapeutic applications of CRISPR/
Cas9 technologies for HIV-1 have been investigated [136].
In addition to its capability to disrupt CCR5 expression
and break down the viral pre-integration complex (PIC)
[63–65], CRISPR/Cas9 has been used to directly mutate
the integrated proviruses in T cell lines. The latently inte-
grated viral genome and viral replication were significantly
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disrupted [137]. Future work should determine whether
the CRISPR/Cas9-mediated silencing can be applied to la-
tently infected resting CD4+ T cells from cART patients.
However, these ‘permanent silencing’ strategies de-
scribed above have some limitations in clinical applica-
tion: (i) delivery difficulties in vivo; (ii) low efficiency of
disrupting target gene(s); and (iii) uncertain safety issues
because of genetic modifications. Thus, development of
silencing small molecule compounds could be a feasible
approach. Indeed, chlorate and guaiacol, which inhibit
the sulfonation pathway, have been found to restrict
HIV-1 reactivation through blocking viral transcription
initiation [138]. One group synthesized and character-
ized several p300-HAT-specific inhibitors. These com-
pounds can inhibit the acetylation of HIV-1-infected T
cells and therefore silence HIV-1 [139]. To reach the
goal of silencing HIV-1 transcription permanently, more
epigenetic modifications around integrated proviruses
need to be identified for developing more new inhibitors.
The absence of HIV-1 Tat could render provirus ‘deeply’
silenced in the cell as described above. Screening the
drugs directly inhibiting Tat can be another alternative
strategy. Didehydro-Cortistatin A (dCA), an analog of
the natural steroidal alkaloid cortistatin A, was found to
suppress HIV-1 transcription through blocking the TAR
binding domain of Tat [140]. It can block provirus re-
activation in several cellular models of HIV-1 latency
and CD4+ T cells isolated from aviremic individuals
[141]. Long-term treatment of this compound can in-
duce a nearly permanent silent state which is insensitive
to current LRAs. Combinations of the inhibitors of
HIV-1 Tat with cART may help to deeply silence the
proviruses in the cells, delay the replenishment of res-
ervoir, and finally shrink it. Another strategy to si-
lence proviruses is to utilize cellular signal pathway
inhibitors. Recently, INK128, one of the mTOR kinase
inhibitors (TOR-KIs), was found to inhibit several
steps of the HIV-1 lifecycle, including CCR5-mediated
entry and the transcription of HIV-1 genes [142]. The
suppression was also achieved in humanized mice
over two weeks. Whether the TOR-KIs can silence
HIV-1 through immunomodulatory mechanisms needs
to be further studied.
Conclusions
Latent infection remains a major obstacle to curing
HIV-1. Several strategies have been proposed and
attempted, including full/partial replacement of the im-
mune system, ‘shock and kill’, and ‘permanent silencing’.
However, to date, most of these strategies are still in the
experimental stage. None of the strategies under discus-
sion can eliminate the reservoir completely and many
challenges still remain. As given above, the viral reser-
voir can be categorized into the ‘shallow’ reservoir and
the ‘deep’ reservoir (Fig. 1). The ‘shock and kill’ strategy
can be very effective in the elimination of the ‘shallow’
reservoir by kicking viruses out of the cells and eliminat-
ing them. As the mechanisms by which the viral reser-
voir is established and maintained are complicated, the
development of novel, effective, and specific LRAs and
the combinations of LRAs functioning in different signal
pathways could be required. In several studies, combina-
tions of prostratin (PKC activator) and DNA methylation
inhibitor, PKC agonists plus BET bromodomain inhib-
itors, HMTi and HDACi, or HDACi plus prostratin
and TNF-α have been attempted and they have been
shown to increase the activation of latently infected
cells [91, 92, 143–145]. Considering some LRAs are
capable of generally reactivating T cells, their toxicity
and potential risk need to be evaluated and moni-
tored closely.
The enhancement of anti-HIV-1 immune surveillance
is a conventional choice for the ‘kill’ strategy. Based on
the effective suppression of bNAbs against HIV-1 in ani-
mal models and clinical trial, combinations of bNAbs
Fig. 1 A feasible strategy for the functional cure of HIV-1. Firstly, ‘shock
and kill’ strategies could be quite useful in kicking out the ‘shallow’
latent viruses and eliminating them. Then, ‘silencing’ strategies, which
permanently inactivate the ‘deeply’ silenced viruses, accompanied by
potent anti-HIV-1 immune surveillance, could subsequently be utilized
to achieve the functional cure of HIV-1
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with LRAs and/or ‘kill’ approaches need to be further
tested. However, given that bNAbs are expensive and are
unlikely used lifelong, these approaches can only be used
to eradicate the ‘shallow’ reservoir for a short time being.
To build up a long-term anti-HIV-1 immune surveil-
lance, cell therapy should be further developed. Previous
data have demonstrated that the immune systems of pa-
tients on cART are not strong enough to eradicate reac-
tivated CD4+ T cells [93]. For this reason, rebuilding
immune surveillance in patients by autologous adoptive
transfer of HIV-1-resistant CD4+ T cells and HIV-1-
specific CD8+ T cells is a feasible strategy (Fig. 2). Novel
gene editing techniques (such as CRISPR/Cas9 system,
high affinity TCRs, and new generations of CAR-Ts)
could be attempted in clinical trials. Additionally, more
strategies pointing at CD8+ T cells from patients on
cART, such as autologous adoptive transfer of ex vivo
expanded HIV-1-specific CD8+ cells, could provide a
strong and expanded CTL response. Furthermore, with
the discovery of broad-spectrum viral-specific CTL re-
sponse, autologous adoptive transfer of HIV-1-specific
CD8+ T cells induced and educated by these broad-
spectrum CTL epitopes could be developed as a thera-
peutic maneuver to promote the clearance of HIV-1-
infected cells. Importantly, the selective expansion of
HIV-1-specific CD8+ TCMex vivo allows the TCM with
the long-term self-renewal ability to respond to and
eradicate any reactivated infected cells. Therefore, the
potent immune surveillance could persistently control
viral replication without the continuation of cART
(Fig. 2). As such, functional cure of HIV-1 for a long
term, even for a lifelong, could be achieved.
To eliminate the ‘deep’ reservoir, highly effective and
specific latency activators and combinations of LRAs
from different pathways can be used to remove the
‘shallow’ reservoir and reduce the size of the ‘deep’ reser-
voir to the greatest extent. Thereafter, strategies such as
the CRISPR/Cas9 system, RNAi, and silencing small
molecule compounds could be utilized to inactivate
these ‘deeply’ silenced viruses. In this case, this strategy
should be used alongside the ‘kill’ strategies to enhance
and maintain the immune surveillance (Fig. 1).
In summary, the ‘shallow’ and ‘deep’ reservoir classifi-
cation can guide the selection of treatment modalities
(Fig. 1). Further investigations on the mechanisms of
HIV-1 latency are required for the development of new
strategies to eradicate viral reservoir. It is also important
to search for novel LRAs to shock out more genetically-
diversified viruses and develop new immunotechnologies
that could recognize and kill the virus-infected cells.
Moreover, new genetic engineering methods capable of
permanently silencing proviruses or even replacing the
immune system entirely also need to be developed.
Despite the failure of current strategies to eliminate
or control HIV-1, the results still provide certain di-
rections for further investigation of therapeutic inter-
ventions. Considering that the HIV-1 reservoir seems
nearly impossible to be eradicated completely, the
dream for ‘functional’ cure of HIV-1 should be the ul-
timate goal.
Fig. 2 Strategies for recovery and optimization of anti-HIV-1 immune surveillance. The combination of bNAbs with autologous adoptive transfer
of HIV-1-specific CD8+ T cells and/or HIV-1-resistant CD4+ T cells could be an effective therapeutic modality for the functional cure of HIV-1
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